Genetic Determinants of Opioids Analgesia

The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00226564

Enrollment

100

Registered

2005-09-27

Start date

1997-08-31

Completion date

Unknown

Last updated

2008-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithiasis

Brief summary

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors. The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Interventions

DRUGAlfentanil

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 20

Exclusion criteria

* Regular use of opioid drugs * Known hypersensitivity to alfentanil

Design outcomes

Primary

Measure	Time frame
Total alfentanil dose used during the procedure.	—
The extent of respiratory depression.	—

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026